Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists


131 Oyster Point Boulevard Suite 400
South San Francisco, CA 94080
Website Company Summary Management Team

Outside board: (May no longer be on the board) Lawrence Steinman (Stanford University School of Medicine) Sean Stalfort (PBM Capital Group Principal) Paul Manning (PBM Capital Group CEO/President) Stephen Zachary (Sands Capital Principal)

Business description: Tolerion is a clinical-stage biopharmaceutical company with a product portfolio built around our novel antigen-specific immune tolerance induction platform. Our first three named product candidates, one in late stage clinical trials, address autoimmune disorders with candidates invented with our proprietary platform. We engineer product candidates that restore balance in autoimmune conditions in which self-antigens (or “autoantigens”) incite a destructive immune response. This approach has the important benefits of targeting the root of the pathogenic immune response without impairing healthy immune function more broadly. This affords significant efficacy and safety advantages relative to other approaches in development.
Partners include: Genentech ;  Juvenile Diabetes Research Foundation

Rounds: 4
Recent Fundings: Jan 2020   Dec 2008
Capital raised: 137.0M
Last Round: 20.0M
Ownership: Private   Ipo Filing
VCs include: Presidio PartnersU.S. Venture PartnersMorgenthaler VenturesLatterell Venture Partners;  Vertical Ventures;  CIDC Consultants;  Montreux Equity Partners;  A.M. PappasAndAssociates;  Prudence Venture Investment Corp;  Grand Cathay Venture Capital Company;  Boston Life Science Venture Corp;  Quintiles PharmaBio Development;  PAC-LINK Bio Management Corp;  unnamed investors
Corporate investors: Lilly Ventures

Last Tweets


Last Mentions

Record updated: Sep 2020
Sector: Biotech
Year Founded: 2001
Headcount: 26-50 as of Jan 2008
Rounds: 4
Recent Fundings: Jan 2020   Dec 2008
Capital Raised: 137.0M
Last Round: 20.0M
Ownership: Private   Ipo Filing